Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review

References

• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;2:55.
   Google Scholar
• O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax. 2015;70:376–378. doi:10.1136/thoraxjnl-2013-204114
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. British thoracic society difficult asthma n: comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71:339–346. doi:10.1136/thoraxjnl-2015-207630
   PubMed Web of Science ®Google Scholar
• von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol. 2014;2:759–767. e752.
   Web of Science ®Google Scholar
• Clark VL, Gibson PG, McDonald VM. What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. ERJ Open Res. 2020;7:254.
   Google Scholar
• Foster JM, McDonald VM, Guo M, Reddel HK. “I have lost in every facet of my life”: the hidden burden of severe asthma. Eur Respir J. 2017;1:50.
   Google Scholar
• Price DB, Trudo F, Voorham J, Xu X, Kerkhof M. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S176026
   PubMed Web of Science ®Google Scholar
• Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370:859–877.
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Adcock IM, Anderson G, et al. The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research. Eur Respir J. 2018;52:1801671. doi:10.1183/13993003.01671-2018
   Web of Science ®Google Scholar
• Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res. 2015;24:631–639. doi:10.1007/s11136-014-0801-x
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832–838. doi:10.1164/ajrccm/147.4.832
   PubMed Web of Science ®Google Scholar
• Pickles K, Eassey D, Reddel HK, Locock L, Kirkpatrick S, Smith L. “This illness diminishes me. What it does is like theft”: a qualitative meta-synthesis of people’s experiences of living with asthma. Health Expect. 2018;21:23–40. doi:10.1111/hex.12605
   PubMed Web of Science ®Google Scholar
• Thamrin C, Nydegger R, Stern G, et al. Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity. Thorax. 2011;66:1036–1042. doi:10.1136/thx.2010.156489
   PubMed Web of Science ®Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–907. doi:10.1034/j.1399-3003.1999.14d29.x
   PubMed Web of Science ®Google Scholar
• Rosenzweig JRC, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med. 2004;98:1157–1165. doi:10.1016/j.rmed.2004.04.001
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Omalizumab for treating severe persistent allergic asthma. TA278. April 2013. Available from: https://www.nice.org.uk/ guidance/ta278. Accessed August 04, 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory eosinophilic asthma. TA431. January 2017. Available from: https://www.nice.org. uk/guidance/ta431. Accessed August 04, 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Reslizumab for treating severe eosinophilic asthma. TA479. October 2017. Available from: https://www.nice.org.uk/ guidance/ta479. Accessed August 04, 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Benralizumab for treating severe eosinophilic asthma. TA565. March 2019 (updated September 2019). Available from: https://www.nice.org.uk/guidance/ta565. Accessed August 04, 2021.
   Google Scholar
•  National Institute for Health and Care Excellence. Bronchial thermoplasty for severe asthma. Interventional procedures guidance. IPG635. December 2018. Available from: https://www.nice.org.uk/guidance/ipg635. Accessed August 04, 2021.
   Google Scholar
• Whalley D, Globe G, Crawford R, et al. Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective. Health Qual Life Outcomes. 2018;16:1–14. doi:10.1186/s12955-018-0970-3
   Web of Science ®Google Scholar
• Kontodimopoulos N, Stamatopoulou E, Brinia A, Talias MA, Ferreira LN. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D. Expert Rev Pharmacoecon Outcomes Res. 2018;18:667–675. doi:10.1080/14737167.2018.1505506
   PubMed Web of Science ®Google Scholar
• Wilson SR, Rand CS, Cabana MD, et al. Asthma outcomes: quality of life. J Allergy Clin Immunol. 2012;129:S88–S123. doi:10.1016/j.jaci.2011.12.988
   PubMed Web of Science ®Google Scholar
• Apfelbacher CJ, Jones CJ, Frew A, Smith H. Validity of three asthma-specific quality of life questionnaires: the patients’ perspective. BMJ Open. 2016;1:6.
   Google Scholar
• Hyland M. The living with asthma questionnaire. Respir Med. 1991;85:13–16. doi:10.1016/S0954-6111(06)80163-0
   PubMed Web of Science ®Google Scholar
• Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol. 1992;45:461–472. doi:10.1016/0895-4356(92)90095-5
   PubMed Web of Science ®Google Scholar
• Hamaker M, Schulkes K, Ten Bokkel Huinink D, van Munster B, van Huis L, van den Bos F. Evaluation and reporting of quality of life outcomes in Phase III chemotherapy trials for poor prognosis malignancies. Quality Life Res. 2017;26(1):65–71. doi:10.1007/s11136-016-1360-0
   PubMed Web of Science ®Google Scholar
• Schandelmaier S, Conen K, Von Elm E, et al. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol. 2015;26:1966–1973. doi:10.1093/annonc/mdv283
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network [document online]. Randomised controlled trials search filter. Available from:https://www.sign.ac.uk/what-we-do/methodology/search-filters/. Accessed September 19, 2019. 
   Google Scholar
• Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Sys Rev. 2009;2010(1). doi:10.1002/14651858.MR000006.pub3
   Web of Science ®Google Scholar
• Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999;115:1265–1270. doi:10.1378/chest.115.5.1265
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mork AC, Stahl E. Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older. Health Qual Life Outcomes. 2005;3:58. doi:10.1186/1477-7525-3-58
   PubMedGoogle Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P, Self-complete A. Measure of Health status for chronic airflow limitation: the St. George’s respiratory questionnaire. Am Rev Respir Dis. 1992;145:1321–1327. doi:10.1164/ajrccm/145.6.1321
   PubMed Web of Science ®Google Scholar
• Sanjuás C, Alonso J, Prieto L, Ferrer M, Broquetas JM, Antó JM. Health-related quality of life in asthma: a comparison between the St george’s respiratory questionnaire and the asthma quality of life questionnaire. Quality Life Res. 2002;11:729–738. doi:10.1023/A:1020897816228
   PubMed Web of Science ®Google Scholar
• Antes G. The New CONSORT Statement. British Medical Journal Publishing Group; 2010.
   Google Scholar
• Austin CD, Gonzalez Edick M, Ferrando RE, et al. A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin Exp Allergy. 2020;50:1342–1351. doi:10.1111/cea.13731
   PubMed Web of Science ®Google Scholar
• Ayars AG, Altman LC, Potter-Perigo S, Radford K, Wight TN, Nair P. Sputum hyaluronan and versican in severe eosinophilic asthma. Int Arch Allergy Immunol. 2013;161:65–73. doi:10.1159/000343031
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Eur J Allergy Clin Immunol. 2004;59:701–708. doi:10.1111/j.1398-9995.2004.00533.x
   Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Eng J Med. 2014;371:1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Virchow JC, Murphy K, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two Phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respi Med. 2020;8:461–474.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 Study. Chest. 2016;150:789–798. doi:10.1016/j.chest.2016.03.032
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Eur J Allergy Clin Immunol. 2011;66:671–678. doi:10.1111/j.1398-9995.2010.02522.x
   Google Scholar
• Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, Phase 2b trial. Lancet Respi Med. 2015;3:692–701. doi:10.1016/S2213-2600(15)00197-6
   PubMed Web of Science ®Google Scholar
• Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respi Med. 2021;9:43–56. doi:10.1016/S2213-2600(20)30412-4
   PubMedGoogle Scholar
• Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J. 2002;20:1088–1094. doi:10.1183/09031936.02.00016502
   PubMed Web of Science ®Google Scholar
• Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20:73–78. doi:10.1183/09031936.02.00278102
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190. doi:10.1067/mai.2001.117880
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respi Med. 2019;7:46–59. doi:10.1016/S2213-2600(18)30406-5
   PubMed Web of Science ®Google Scholar
• Busse WW, Brusselle GG, Korn S, et al. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. Eur Respir J. 2019;2:53.
   Google Scholar
• Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116–124. doi:10.1164/rccm.200903-0354OC
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–1132. doi:10.1164/rccm.201103-0396OC
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respi Med. 2014;2:879–890. doi:10.1016/S2213-2600(14)70201-2
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respi Med. 2015;3:355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F. Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma. Respir Med. 2010;104:1608–1617. doi:10.1016/j.rmed.2010.07.011
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respi Med. 2017;5:390–400. doi:10.1016/S2213-2600(17)30125-X
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Eng J Med. 2011;365:1088–1098. doi:10.1056/NEJMoa1106469
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810. doi:10.1016/j.chest.2016.03.018
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM. Tezepelumab in adults with uncontrolled asthma. N Eng J Med. 2017;377:936–946. doi:10.1056/NEJMoa1704064
   PubMed Web of Science ®Google Scholar
• Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Eng J Med. 2007;356:1327–1337. doi:10.1056/NEJMoa064707
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, Van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003;111:278–284. doi:10.1067/mai.2003.54
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144:411–419. doi:10.1378/chest.12-1961
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respi Med. 2016;4:699–707. doi:10.1016/S2213-2600(16)30179-5
   PubMed Web of Science ®Google Scholar
• Goorsenberg AWM, Hooghe JNS, Srikanthan K, et al. Bronchial Thermoplasty induced airway smooth muscle reduction and clinical response in severe asthma: the TASMA randomized trial. Am J Respir Crit Care Med. 2020;203(2):175.
   Web of Science ®Google Scholar
• Gottlow M, Svensson DJ, Lipkovich I, et al. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma. BMC Pulm Med. 2019;19:129. doi:10.1186/s12890-019-0889-4
   Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Eng J Med. 2009;360:973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Hall CS, Quirk JD, Goss CW, et al. Single-session bronchial thermoplasty guided by 129Xe Magnetic Resonance Imaging. A pilot randomized controlled clinical trial. Am J Respir Crit Care Med. 2020;202:524–534. doi:10.1164/rccm.201905-1021OC
   Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582. doi:10.7326/0003-4819-154-9-201105030-00002
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632–638. doi:10.1111/j.1365-2222.2004.1916.x
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83:520–528. doi:10.1159/000334701
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Eur J Allergy Clin Immunol. 2005;60:309–316. doi:10.1111/j.1398-9995.2004.00772.x
   Google Scholar
• Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154–159. doi:10.1016/S1081-1206(10)62170-9
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140:162. doi:10.1016/j.jaci.2016.08.054
   PubMed Web of Science ®Google Scholar
• Li J, Kang J, Wang C, et al. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study. Allergy Asthma Immunol Res. 2016;8:319–328. doi:10.4168/aair.2016.8.4.319
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Kjarsgaard M, Radford K, et al. Omalizumab in patients with severe asthma and persistent sputum eosinophilia. Allergy Asthma Clin Immunol. 2019;15:21. doi:10.1186/s13223-019-0337-2
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Eng J Med. 2017;376:2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology. 2009;14:1156–1165. doi:10.1111/j.1440-1843.2009.01633.x
   PubMed Web of Science ®Google Scholar
• Ohta K, Adachi M, Tohda Y, et al. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int. 2018;67:266–272. doi:10.1016/j.alit.2017.10.004
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Eng J Med. 2014;371:1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Panettieri RA, Sjobring U, Peterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respi Med. 2018;6:511–525. doi:10.1016/S2213-2600(18)30184-X
   PubMed Web of Science ®Google Scholar
• Panettieri RA, Welte T, Shenoy KV, et al. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase iiib randomized, controlled trial (SOLANA). J Asthma Allergy. 2020;13:115–126. doi:10.2147/JAA.S240044
   PubMed Web of Science ®Google Scholar
• Pasha MA, Jourd’Heuil D, Jourd’Heuil F, et al. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients. Allergy Asthma Proce. 2014;35:241–249. doi:10.2500/aap.2014.35.3741
   Web of Science ®Google Scholar
• Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176:1185–1191. doi:10.1164/rccm.200704-571OC
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A Phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330–338. doi:10.1183/09031936.00223411
   PubMed Web of Science ®Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma. 2012;49:288–293. doi:10.3109/02770903.2012.660297
   PubMed Web of Science ®Google Scholar
• Russell RJ, Chachi L, FitzGerald JM, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respi Med. 2018;6:499–510. doi:10.1016/S2213-2600(18)30201-7
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Matsuki S, Irie S, et al. Randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy Japanese men. Clin Pharmacol Drug Dev. 2020;9:833–840. doi:10.1002/cpdd.775
   Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261. doi:10.1183/09031936.01.00092101
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Eliraz A, Asher I, Berkman N, Elbirt D. The beneficial effects of Xolair (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - The Israeli arm of the INNOVATE study. Israel Med Assoc J. 2007;9:472–475.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Eur J Allergy Clin Immunol. 2004;59:709–717. doi:10.1111/j.1398-9995.2004.00550.x
   Google Scholar
• Zeitlin PL, Leong M, Cole J, et al. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the phase iiib ALIZE trial. J Asthma Allergy. 2018;11:181–192. doi:10.2147/JAA.S172338
   Web of Science ®Google Scholar